We have examined the susceptibility to acyclovir and frequency of acyclovir-resistant viruses in herpes simplex virus type (HSV) 2 clones isolated directly from genital lesions of 11 patients who had taken suppressive therapy (200 mg/day) for 1-9 years and 15 patients naive to acyclovir. Suppressive therapy significantly reduced the incidence of recurrence and the severity of the skin lesions. HSV samples from genital lesions were directly inoculated into Vero cells, and viral clones were isolated in the absence and presence of 10 µg/ml acyclovir. Five-hundred-and-ninetytwo clones, isolated in the absence of acyclovir, were subjected to the acyclovir susceptibility test, and 155 clones isolated in the presence of acyclovir were analysed for the mechanisms of resistance to acyclovir. There were no significant differences in the susceptibility to acyclovir, the frequency of acyclovir-resistant virus and the ratio of thymidine kinase-deficient viruses in acyclovir-resistant viruses between the two groups. The frequency of acyclovir-resistant clones was about three per 10000 plaque forming units (PFU), and genital lesions contained up to 3x10 6 PFU of replicating virus in the specimens from the patients with genital herpes with or without acyclovir-suppressive therapy. Thus, the low dose of acyclovir suppressive therapy did not affect the susceptibility to acyclovir or increase the frequency of acyclovir-resistant viruses in the genital lesions.
Acyclovir (Elion et al., 1977) is one of the current treatments of choice for herpes simplex virus (HSV) infection and is used mainly for short-term treatment in acute or recurrent infections. Long-term continuous acyclovir therapy for recurrent herpes simplex is considered effective and safe (Straus et al., 1984; Mostrow et al., 1988; Kaplowitz et al., 1991; Fife et al., 1994; Kimberlin et al., 1995; Centers for Disease Control and Prevention, 1998) . However, an increasing number of chronic HSV infections in immunocompromised hosts, such as patients in the late phase of HIV-infection, require long-term treatment. In such cases, the emergence of drug-resistant viruses might occur (Straus et al., 1988; Erlich et al., 1989; Gray et al., 1989; Englund et al., 1990; Kaplowitz et al., 1991; Balfour et al., 1994; Chistophers et al., 1998; Swetter et al., 1998 ).
An oral acyclovir was licensed for the first time in Japan in 1988, but suppressive and preventive administration for genital herpes is not permitted. The only recommended regimen for episodes of recurrent infection is acyclovir 200mg orally, five times a day, for 5 days. In our 379 Japanese patients with genital herpes the mean rate of recurrences caused by HSV-1 is 1.0 per year, while that for HSV-2 is 9.7 per year. We use 200 mg oral acyclovir once a day for daily low-dose acyclovir suppressive therapy in our patients with genital herpes caused by HSV-2 who have six or more recurrences per year. Thus, this study is designed to characterize the affect of long-term, low-dose acyclovir suppressive therapy on susceptibility to acyclovir and frequency of acyclovirresistance for HSV-2 isolated from genital lesions. In order to perform this investigation, HSV-2 was isolated as clones directly from a smear of genital lesions in the presence and absence of 10 µg/ml acyclovir. Then the amount of total virus and the frequency of acyclovir resistant virus in the smear samples was determined in patients on suppressive therapy and in those naive to acyclovir therapy. We could not find any affect of long-term, low-dose acyclovir suppressive therapy on the susceptibility to acyclovir and on the frequency of acyclovir-resistance of the virus population isolated directly from lesions of genital herpes. This finding suggests that long-term, low-dose acyclovir suppressive therapy for Introduction 1-9 years has not altered the nature of the latent virus in the ganglia, even using highly sensitive assay methods to detect acyclovir-resistant virus in the genital lesions.
Materials and Methods

Patients
Sixty-two patients (25 women, 37 men; mean age 44 years, range 26-73 years) who had given informed consent, had HSV-2 isolated from the genital lesions and had six or more recurrences per year, were taken from a cohort of Japanese patients with recurrent genital herpes who had received acyclovir therapy and had been followed between 1990 and 1998. The patients had been assigned a dosage of 200 mg once daily between 1990 and 1998. Single daily doses produced less complete suppression of genital herpes. Eighteen of the 62 patients (29%) had not experienced a herpes episode in 1998, and 18 (29%) had a single episode, 12 (19%) two episodes, seven (11%) three episodes, five (8%) four episodes, one (2%) five episodes and one (2%) six episodes. Therefore, among 62 patients who have been receiving suppressive therapy in 1998, 44 (71%) had one and more recurrences. Eighteen of the 44 patients who revealed symptomatic recurrences could visit our hospital, and specimens for HSV culture were obtained from their genital lesions. We also selected 16 patients (12 women and four men: mean age 49 years, range 25-77 years) with genital herpes and a history of six or more recurrences per year. The 16 patients had HSV-2 isolated from genital lesions, and had not received acyclovir therapy. All patients were healthy and received no immunosuppressive medications. Thus, we obtained specimens from 18 patients treated with acyclovir suppressive therapy, and from an additional 16 patients who had not received treatment with antiviral agents.
Isolation of acyclovir-resistant virus from the artificial mixtures of acyclovir-sensitive and thymidine kinase-deficient, acyclovir-resistant viruses
We have performed the quantitation of acyclovir-resistant virus from the artificial mixtures of acyclovir-sensitive and thymidine kinase (TK)-deficient, acyclovir-resistant viruses. Acyclovir-resistant and -sensitive viruses were mixed at the different ratios and inoculated into Vero cell cultures. One set of monolayers was overlaid with methylcellulose without acyclovir and another with methylcellulose containing 10 µg/ml of acyclovir. When the plaques appeared, the number of plaques was counted under a dissecting microscope.
Direct isolation of HSV-2 as clones from the lesions of genital herpes
Vero cells were grown in Eagle's minimum essential medium supplemented with 5% bovine serum and maintained with 2% bovine serum. The procedures for the isolation of virus clones and their susceptibility assay have been reported previously (Hasegawa et al., 2001) . Smears from genial lesions were suspended in 1 ml of PBS and centrifuged at 12 000 rpm for 5 min at 4°C. The supernatant was 10-fold serially diluted with PBS, and 0.2 ml from each dilution was inoculated into two sets of Vero cell monolayers in 60mm plastic dishes for 1 h. One set of monolayers was overlaid with methylcellulose without acyclovir and another with methylcellulose containing 10 µg/ml of acyclovir. When the plaques appeared, they were counted under a dissecting microscope, and clones were directly isolated from the monolayers with and without acyclovir. The isolated clones were grown in Vero cell cultures and subjected to a susceptibility assay to antiviral agents. Virus titres in the samples were determined from the cultures without acyclovir, and the numbers of acyclovir-resistant viruses was determined from the cultures with acyclovir. The frequency of acyclovir-resistant viruses in the sample was defined as the number of resistant virus per 10 4 viruses.
Determination of susceptibility to antiviral drugs
The susceptibilities of viruses to antiviral drugs were determined by examining the inhibitory concentration for 50% plaque reduction (IC 50 ) (Crumpacker et al., 1979; Biron & Elion, 1980; Kurokawa et al., 1993 Kurokawa et al., , 1998 Hasegawa et al., Diluted TK-deficient acyclovir-resistant virus was mixed with acyclovir-sensitive virus at three different concentrations as indicated: mixture 1 (undiluted TK-deficient virus), 2 (twice dilution) and 3 (5 times dilution). Virus titre was determined in the presence and absence of acyclovir (10 mg/ml) and the ratio indicates the comparative values of the virus titre with acyclovir over the titre without acyclovir. ACV, acyclovir; PFU, plaque forming unit.
2001). Antiviral drugs used were acyclovir (kindly supplied by Nippon Wellcome KK, Osaka, Japan), iododeoxyuridine (IDU) and phosphonoacetic acid (PAA) (purchased from Seikagakukogyo, Japan). Briefly, confluent cell monolayers in 60 mm plastic dishes in duplicate or triplicate were infected with 100 plaque forming units (PFU) of virus for 1 h, and incubated in a nutrient methylcellulose medium containing different concentrations of the drugs. After the appearance of cytopathic effect, the cells were fixed with 5% neutral formalin and stained with methylene blue, and the number of plaques was counted with a dissecting microscope. The IC 50 was determined graphically.
Statistical analysis
The Student's t-test and χ 2 Fisher test was used to evaluate the statistical significance of the difference in the IC 50 values among the isolates, and probability values (P) less than 0.05 were considered to be statistically significant.
Results
Isolation of acyclovir-resistant virus from the artificial mixtures of acyclovir-sensitive and TKdeficient, acyclovir-resistant viruses
The quantitation of acyclovir-resistant virus from the artificial mixtures of acyclovir-sensitive and TK-deficient, acyclovir-resistant viruses is shown in Table 1 . Acyclovirresistant viruses showed 73% of virus titre in the presence of 10 µg/ml acyclovir. Diluted TK-deficient virus was mixed with acyclovir-sensitive virus at three different mixtures: (1) undiluted TK-deficient virus; (2) twice dilution; and (3) five times dilution. Thus, the artificial mixtures were prepared at the various mixtures of acyclovir-sensitive and -resistant viruses, and the ratio of acyclovir-resistant viruses per total virus titre was consistent with the mixing ratio of the two viruses. The artificial mixture experiment verified the quantitative assay system for detecting acyclovir-resistant virus in the samples containing acyclovirsensitive and -resistant virus.
Efficacy of low-dose suppressive therapy
Virus titre and frequency of acyclovir-resistant virus in genital samples. HSV-2 clones of 13 samples were isolated from the genital lesions of 11 out of 18 patients on acyclovir treatment and from 15 out of 16 patients without treatment. Table 2 summarizes the results of virus isolation, the susceptibility to acyclovir and the frequency of acyclovir-resistant virus in the samples directly isolated from genital lesions of patients on suppressive therapy. The mean IC 50 of clones from genital lesions was similar among 13 samples from the 11 patients on acyclovir therapy. Total virus amount, expressed as PFU per ml per smear, from skin lesions ranged from 1 to 2×l0 6 PFU per smear, and six samples of 13 contained more than 10 4 PFU. This variation in virus titre may be mainly due to the stage of the skin lesions. Acyclovir-resistant virus was defined as viruses with an IC 50 of more than 10 µg/ml of acyclovir. The frequency of acyclovir-resistant viruses in the samples ranged from 0.0 to 9.9 PFU per 10 4 PFU of the isolated clones in the samples with more than 10 4 PFU and with acyclovirresistant virus. Table 3 shows the results of virus isolation, the susceptibility to acyclovir and the frequency of acyclovir resistant virus in the samples directly isolated from genital lesions of patients naive to acyclovir therapy. Similar results from patients on suppressive therapy were observed for each item in Table 3 .
Comparison of the results between patients on suppressive therapy and those naive to acyclovir is summarized in Table 4 . There was no significant difference in the virus amount and frequency of acyclovir-resistant virus per I0 4 PFU of the sample between the two groups.
Characterization of acyclovir-resistant viruses in the genital lesions
In order to characterize the mechanism of acyclovir resistance in the viruses from the skin lesions, we categorized these acyclovir-resistant viruses by the pattern of susceptibility and resistance to IDU and PAA as shown in Table 4 . The acyclovir-resistant viruses were defined as those with an IC 50 value of more than 10 µg/ml of acyclovir. TK-deficient M Honda et al. viruses were resistant to IDU but were similarly as sensitive to PAA as the acyclovir-sensitive viruses. TK-altered virus was partially resistant to IDU but sensitive to PAA. DNA polymerase altered virus was sensitive to IDU but resistant or hypersensitive to PAA. The majority of the acyclovirresistant viruses were TK-deficient viruses in both patients groups, and both groups contained some TK-altered and DNA polymerase-altered viruses. There was also no significant difference in the pattern of resistance to acyclovir between patients with suppressive therapy and those naive to acyclovir (Table 5) . Thus, no significant difference between the two groups of patients was observed in the frequency of acyclovir-resistant viruses in 10 4 PFU of the sample from genital lesions and their pattern of acyclovir resistance in the TK and DNA polymerase genes. This finding suggested an absence of induction of acyclovir-resistant viruses in patients with genital herpes during chronic lowdose suppressive therapy with low-dose acyclovir.
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Discussion
Acyclovir is an effective and selective inhibitor of HSV replication. The mechanism of action of this purine nucleoside analogue against HSV implies an initial drug phosphorylation by the viral TK. Acyclovir-monophosphate is then phosphorylated by cellular enzymes to the triphosphate form. The latter is a competitive inhibitor of viral DNA polymerase and also acts as a chain terminator. Several analyses of immunocompetent patients cohorts have been reported that establish the long-term safety and efficacy of suppressive acyclovir therapy (Mertz et al., 1988; Kroon et al., 1990; Wald et al., 1997; Baker et al., 1999) . Clinically significant resistance to acyclovir has been almost exclusively seen in the immunocompromised population. Acyclovirresistant HSV have been reported in patients with immunodeficiency in the IC 50 assay (Erlich et al., 1989; Englund et al., 1990; Christophers et al., 1998) . The degree of immunosuppression, and low doses and prolonged use of acyclovir are considered important factors for the development of drug resistance. Phenotypically, viral resistance to acyclovir is related to one of the following four mechanisms: complete deficiency in viral TK activity (TK-deficient), viral TK protein with altered substrate specificity (TK-altered), decreased activity or production of low amounts of viral TK (TK-low producer) and viral polymerase with altered substrate specificity (Sasadeusz et al., 1997; Hasegawa et al., 2001) .
In conventional virus isolation, virus is isolated as the mixture of individual clones in skin lesions. The sensitivity of the isolated virus to acyclovir is conventionally evaluated by IC 50 and IC 90 values, IC 90 indicating the presence of less sensitive virus in the virus inoculum. However, at least 10% of the inoculum virus sample should exhibit less sensitivity to acyclovir in order to affect the value of IC 90 . In this study we used a highly sensitive method to detect acyclovir-resistant virus in the specimens from the genital lesions. We directly evaluated the amount acyclovir-resistant virus clones in 10 4 PFU of virus in the specimens. In this aspect, our assay system is at least 1000 times more sensitive than IC 90 in detecting acyclovir-resistant virus in clinical specimens. This highly sensitive method was used to assess and compare the frequency of acyclovir-resistant virus directly isolated from genital lesions of patients on acyclovir-suppressive therapy, with the frequency of resistant virus isolated from patients naive to acyclovir. This method may be powerful in detecting the increase in acyclovir-resistant virus in the lesions in the early phase of replacement from acyclovir-sensitive virus to acyclovir-resistant virus.
The experiment using the artificial mixtures of acyclovirresistant and -sensitive viruses verified the assay system for the quantitative detection of acyclovir-resistant viruses from their different mixtures. Based on this assay system, we report the comparison of acyclovir-resistant isolates from patients who had genital herpes treated with suppressive acyclovir therapy, and isolates from patients who had not received treatment with antiviral agents or any other treatment. There was no significant difference between the two groups in the frequency of resistant virus and their pattern of resistance to acyclovir. This is consistent with previous studies concerning the susceptibility of clinical isolates from patients on acyclovir suppressive therapy in the aspect of IC 50 values (Al-Hasani et al., 1986; Mertz et al., 1988; Kroon et al., 1990; Molin et al., 1991; Baker 1994) . Furthermore, the pattern of acyclovir resistance of the acyclovir-resistant viruses was similar for the TK and DNA polymerase between the two groups.
HSV has widely occurring natural variants, and Parris and Harrington (1982) reported the presence of acyclovirresistant virus in the clinically isolated virus stock at about 10 -4 as determined by plating efficiency. Interestingly, most of them contained alterations in the DNA polymerase gene locus. In our study, we have directly isolated the acyclovirresistant variants as clones in the presence of acyclovir from the genital lesions, which contained replicating virus, and the frequency was about three per 10000 PFU. HSV-2 clinical isolates grown in tissue cultures showed about 11 per 10000 PFU (Hasegawa et al., 2001) . Therefore, the frequency of the acyclovir-resistant virus in the genital lesions was the same as the naturally occurring frequency of acyclovir-resistant virus. Furthermore, the proportion of TKdeficient virus in the acyclovir-resistant viruses coincided with the frequency of clinical isolates with acyclovir phenotypic resistance (Kimberlin et al., 1995; Chistophers et al., 1998) . There was no significant difference between the patients groups in the susceptibility or frequency of acyclovir-resistant virus, and the ratio of TK-deficient virus in the acyclovir-resistant variants. This finding suggests that there is no induction of acyclovir-resistant viruses in patients with genital herpes during chronic suppressive therapy with acyclovir.
